Načítá se...
Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has...
Uloženo v:
| Vydáno v: | Onco Targets Ther |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452813/ https://ncbi.nlm.nih.gov/pubmed/31040693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S141040 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|